Clinical Trials Browser

Astrocytoma, Burkitt Lymphoma, Glioblastoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoproliferative Disorders, Mycosis Fungoides, Oligodendroglioma, Recurrence, Sezary Syndrome, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Central Nervous System Neoplasms, Lymphoma, Large-Cell, Anaplastic, Neoplasms, Neuroepithelial, Optic Nerve Glioma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

NCT01568632 2012-11-21

Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma

Phase 1 Withdrawn

Lymphoid

Lymphoma

Clinical Trials

IMAGINE

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma

Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma